Phospholipidosis as a Function of Basicity, Lipophilicity, and Volume of Distribution of Compounds

被引:81
作者
Hanumegowda, Umesh M. [1 ]
Wenke, Gottfried [2 ]
Regueiro-Ren, Alicia [3 ]
Yordanova, Roumyana [4 ]
Corradi, John P. [4 ]
Adams, Stephen P. [1 ]
机构
[1] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Toxicol, Wallingford, CT 06492 USA
[2] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Analyt Sci, Wallingford, CT 06492 USA
[3] Bristol Myers Squibb Co, Res & Dev, Dept Discovery Chem, Wallingford, CT 06492 USA
[4] Bristol Myers Squibb Co, Res & Dev, Dept Bioinformat, Wallingford, CT 06492 USA
关键词
DRUG-INDUCED PHOSPHOLIPIDOSIS; INDUCED GENERALIZED LIPIDOSIS; RAT-LIVER; ULTRASTRUCTURAL ALTERATIONS; PHARMACOKINETIC PARAMETERS; TRICYCLIC ANTIDEPRESSANTS; GENE-EXPRESSION; MYELOID BODIES; HEPG2; CELLS; GENTAMICIN;
D O I
10.1021/tx9003825
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drug-induced phospholipidosis (PLD) is an adaptive histologic alteration that is seen with various marketed drugs and often encountered during drug development. Various in silico and in vitro cell-based methods have been developed to predict the PLD-inducing potential of compounds. These methods rely on the inherent physicochemical properties of the molecule and, as such, tend to overpredict compounds as PLD inducers. Recognizing that the distribution of compounds into tissues or tissue accumulation is likely a key factor in PLD induction, in addition to key physicochemical properties, we developed a model to predict PLD in vivo using the measures of basicity (pK(a)), lipophilicity (ClogP), and volume of distribution (V(d)). Using sets of PLD inducers and noninducers, we demonstrate improved concordance with this method. Furthermore, we propose a screening paradigm that includes a combination of various methods to predict the in vivo PLD-inducing potential of compounds, which may be especially useful in lead identification and optimization processes in drug discovery.
引用
收藏
页码:749 / 755
页数:7
相关论文
共 74 条
[1]   Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines [J].
Agwuh, Kenneth N. ;
MacGowan, Alasdair .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (02) :256-265
[2]  
ANDERSON IB, 2007, POISONING DRUG OVERD
[3]   Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells [J].
Atienzar, Franck ;
Gerets, Helga ;
Dufrane, Simon ;
Tilmant, Karen ;
Cornet, Miranda ;
Dhalluin, Stephane ;
Ruty, Bernard ;
Rose, Geoffrey ;
Canning, Michael .
TOXICOLOGICAL SCIENCES, 2007, 96 (01) :101-114
[4]   Scaling basic toxicokinetic parameters from rat to man [J].
Bachmann, K ;
Pardoe, D ;
White, D .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1996, 104 (04) :400-407
[5]   Biomarkers to monitor drug-induced phospholipidosis [J].
Baronas, Elizabeth Tengstrand ;
Lee, Ju-Whei ;
Alden, Carl ;
Hsieh, Frank Y. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 218 (01) :72-78
[6]   Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE [J].
Bhandari, Neetesh ;
Figueroa, David J. ;
Lawrence, Jeffrey W. ;
Gerhold, David Lee .
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2008, 6 (03) :407-419
[7]   Iatrogenic phospholipidosis mimicking Fabry disease [J].
Bracamonte, Erika R. ;
Kowalewska, Jolanta ;
Starr, Jonathan ;
Gitomer, Jeremy ;
Alpers, Charles E. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 48 (05) :844-850
[8]   PHARMACOKINETICS OF ZIMELIDINE - SYSTEMIC AVAILABILITY OF ZIMELIDINE AND NORZIMELIDINE IN HUMAN VOLUNTEERS [J].
BROWN, D ;
SCOTT, DHT ;
SCOTT, DB ;
MEYER, M ;
WESTERLUND, D ;
LUNDSTROM, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 17 (02) :111-116
[9]   Pharmacokinetics of Sertindole and its Metabolite Dehydrosertindole in Rats and Characterization of their Comparative Pharmacodynamics based on In Vivo D2 Receptor Occupancy and Behavioural Conditioned Avoidance Response [J].
Bundgaard, Christoffer ;
Larsen, Frank ;
Kreilgaard, Mads ;
Brennum, Lise T. ;
Olsen, Christina Kurre .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2009, 30 (04) :209-220
[10]  
BURTON LL, 2006, PHARMACOL BASIS THER, P1794